Pfizer Global Product Development News Today : Breaking News, Live Updates & Top Stories | Vimarsana

FDA Approves Braftovi and Mektovi for Some Patients with Metastatic NSCLC

Braftovi (encorafenib) with Mektovi (binimetinib) has been approved for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation, the agency announced on Wednesday evening.

Foundationone cdxChris boshoffPfizer global product developmentDrug administrationFoundationone liquidSupplemental new drug applicationClinical oncologyLung cancer

Pfizer Inc Leaders, Founders, and Executives: Who Are They?

Pfizer is a research-based pharmaceutical and biomedical giant. Get to know the Pfizer Inc. leaders, founders, and executives here

New yorkUnited statesWilliam paoJosephj echevarriaAngela hwangShantanu narayenAamar malikDanr littmanMike mcdermottRonalde blaylockSally susmanSusan desmond hellmannJamesc smithOlidia fonsecaMikael dolstenDoug lankler

Cardiff Oncology Advances Colorectal Cancer Treatment - San Diego Business Journal

Cardiff Oncology Advances Colorectal Cancer Treatment - San Diego Business Journal
sdbj.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sdbj.com Daily Mail and Mail on Sunday newspapers.

San diegoUnited statesMark erlanderJamie levineAdam schayowitzCardiff oncology incPfizer global product developmentCardiff oncologyPfizer ignite

Cardiff Oncology Reports Second Quarter 2023 Results and Provides Business Update

/PRNewswire/ Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug.

Richa kumariJames levineMark erlanderKiki patelGilmartin groupExchange commissionPfizer global product developmentDana farber cancer institutePrnewswire cardiff oncology incCardiff oncology incMedicine team group lead for breast cancerTaft communicationsCardiff oncologyChief executive officerPfizer igniteVice president

Cardiff Oncology Announces New Lead Program in First-Line Metastatic Colorectal Cancer and Expanded Pfizer Relationship

- Advance to first-line RAS-mutated mCRC follows the strong signal from new clinical and preclinical data, and agreement with FDA - - First-line mCRC represents substantial increase in patient.

Kiki patelMark erlanderJames levineAdam schayowitzFairooz kabbinavarRicha kumariMedicine team group lead for breast cancerGilmartin groupTaft communicationsPrnewswire cardiff oncology incCardiff oncology incExchange commissionPfizer incPfizer global product developmentPfizer igniteCardiff oncology